Chilean AI-led food tech startup NotCo has unveiled a botanical GLP Booster powder that uses food as a natural Ozempic ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Jim Cramer recently talked about the market selloff and how years of profits are lost within days when panic hits the market: ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Economists around the world expect muted U.S. economic growth in the coming quarters, and some indicators have shown an increased likelihood of a 2025 recession in recent weeks. It may become ...

The study used Mounjaro, which is not yet approved specifically for weight management. Over the last few years, there has been an increase in the use of glucagon-like peptide-1 receptor agonists ...

Perplexity AI is an AI-driven search engine and chatbot that uses large language models (LLMs) to answer user queries by drawing information from the web and providing cited sources within its ...

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent unintended consequences.

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

Eli Lilly's weight-loss jab Mounjaro has been cleared for rollout by the NHS in England, with around 3.4 million people eligible, but will be made available in stages to limit the financial impact.

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...